Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-29T08:04:38.720Z Has data issue: false hasContentIssue false

33 - Psychopharmacological treatment in liaison psychiatry

from Part IV - Treatment

Published online by Cambridge University Press:  10 December 2009

By
Ulrik Fredrik Malt  and
Geoffrey G. Lloyd
Edited by
Geoffrey Lloyd  and
Elspeth Guthrie
Geoffrey Lloyd
Affiliation:
Priory Hospital, London
Elspeth Guthrie
Affiliation:
University of Manchester
Get access

Summary

There is still limited systematic research on the effectiveness of psychotropic drugs used in liaison psychiatry settings. All drugs available in clinical psychiatry for the treatment of psychiatric disorders can be used in liaison settings. However, before choosing a specific drug, liaison psychiatrists must address additional important issues beyond those related to the indication for a psychotropic drug. Most psychotropic drugs used today are aimed at g-protein coupled receptors such as serotonergic (5HT). The availability of psychotropic drugs varies to some extent between countries within the European Union. This chapter discusses the most frequently used drugs. Depressive disorders accompanying physical illness should be treated to improve quality of life and treatment adherence. The main indications in liaison psychiatry settings are behavioural disorders caused by organic brain dysfunction including temporal lobe epilepsy, acute mania, pain disorders and prophylactic treatment of bipolar disorders.

Keywords

depressive disorderg-protein coupled receptorsliaison psychiatrypsychotropic drugtemporal lobe epilepsy
Type
Chapter
Information
Handbook of Liaison Psychiatry , pp. 763 - 794
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cipriani, A., Barbui, C. and Geddes, J. R. (2005). Suicide, depression and antidepressants. British Medical Journal, 330, 373–4.Google Scholar
Cole, M. G. and Bellavance, F. (1997). Depression in elderly medical inpatients: a metaanalysis of outcomes. Canadian Medical Association Journal, 157, 1055–60.Google Scholar
Dmochowski, R. R., Miklos, J. R., Norton, P. A., et al.; Duloxetine Urinary Incontinence Study Group. (2003) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Journal of Urology, 170, 1259–63.Google Scholar
Fenton, M., Coutinho, E. S. F. and Campbell, C. (2003). Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons.
Gill, D. and Hatcher, S. (2003). Antidepressants for depression in medical illness (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons.
Hammerness, P., Basch, E., Ulbricht, C., et al. Natural Standard Research Collaboration. (2003). St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics, 44, 271–82.Google Scholar
Harrigan, E. P., Miceli, J. J., Anziano, R., et al. (2004). A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology, 24, 62–9.Google Scholar
Huyse, F. J., Touw, D. J., Schijndel, R. S., et al. (2006). Psychotropic drugs and the perioperative period; a proposal for a guideline in elective surgery. Psychosomatics, 47, 8–22.Google Scholar
Isojarvi, J. I. (2003). Reproductive dysfunction in women with epilepsy. Neurology, 61(Suppl. 2), S27–34.Google Scholar
Jin, Y., Desta, Z., Stearns, V., et al. (2005). CYP2D6 genotype. Antidepressant use and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute, 97, 30–9.Google Scholar
Kuhn, K. U., Quednow, B. B., Thiel, M., et al. (2003). Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behaviour, 4, 674–9.Google Scholar
Leucht, S., Barnes, T. R., Kiesling, W., et al. (2003). Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomized controlled trials. American Journal of Psychiatry, 160, 1209–22.Google Scholar
Lingjærde, O., Jørgensen, J., Støren, R., et al. (1995). A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatrica Scandinavica, 92, 125–31.Google Scholar
Malt, U. F., Robak, O. H., Madsbu, H.-P., et al. (1999). The Norwegian naturalistic treatment study of depression in general practice (NORDEP) – I: Randomised double-blind study. British Medical Journal, 318, 1180–4.Google Scholar
Misri, S. and Kostaras, X. (2002). Benefits and risks to mother and infant of drug treatment for postnatal depression. Drug Safety, 25, 903–11.Google Scholar
Moretti, M. E., Koren, G., Verjee, Z., et al. (2003). Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Therapeutic Drug Monitoring, 25, 364–6.Google Scholar
Oberlander, T. F., Misri, S., Fritzgerald, C. F., et al. (2004). Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Journal of Clinical Psychiatry, 65, 230–7.Google Scholar
Reisberg, B., Doody, R., Stoffler, A., et al. (2003) and the memantine study group. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 348, 1333–41.Google Scholar
Richmond, R. and Zwar, N. (2003). Review of bupropion for smoking cessation. Drug and Alcohol Review, 22, 203–20.Google Scholar
Rodriguez-Landa, J. F. and Contreras, C. M. (2003). A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine, 10, 688–99.Google Scholar
Sa, D. S., Kapur, S. and Lang, A. E. (2001). Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. Clinical Neuropharmacology, 24, 242–4.Google Scholar
Scott, A. I. F. (2005). College guidelines on electroconvulsive therapy: an update for prescribers. Advances in Psychiatric Treatment, 11, 150–6.Google Scholar
Skrobik, Y. K., Bergeron, N., Dumont, M., et al. (2004). Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Medicine, 30, 444–9.Google Scholar
Soares, K. V. S. and McGrath, J. J. (2003). Vitamin E for neuroleptic-induced tardive dyskinesia (Cochrane Review). In: The Cochrane Library, Issue 4, Chichester: John Wiley & Sons.
Spigset, O. and Hägg, S. (1998). Excretion of psychotropic drugs into breast milk. CNS Drugs, 9, 111–34.Google Scholar
Strain, J. J., Chiu, N. M., Sultana, K., et al. (2004). Psychotropic drug versus psychotropic drug update. General Hospital Psychiatry, 26, 87–105.Google Scholar
Temple, R., Aldridge, V., Greenwood, R., et al. (2003). Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population-based study. British Medical Journal, 325, 1275–6.Google Scholar
Williams, J. H. and Hepner, D. L. (2004). Risperidone and exaggerated hypotension during a spinal anesthetic. Anesthesia and Analgesia, 98, 240–1.Google Scholar
Wynn, Z. J. and Cummings, J. L. (2004). Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 17, 100–8.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×